Understanding GERD symptoms in the clinical setting

Drugs of Today

Volumn 41, Issue SUPPL. B, 2005, Pages 13-17

  Holtmann, Gerald ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE; PANTOPRAZOLE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CLINICAL PRACTICE; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; ESOPHAGUS INJURY; GASTROESOPHAGEAL REFLUX; HUMAN; PREVALENCE; RISK FACTOR; STOMACH MUCOSA LESION; SYMPTOMATOLOGY; WESTERN HEMISPHERE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS; GASTROESOPHAGEAL REFLUX; HUMANS; INTESTINAL MUCOSA; OMEPRAZOLE; QUESTIONNAIRES; SULFOXIDES;

EID: 23044444809     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.1.875775     Document Type: Conference Paper

References (8)

1. Holtmann, G. Reflux disease: The disorder of the third millennium. Eur J Gastroenterol Hepatol 2001, 13(Suppl. 1): S5-11.
2. Lagergren, J., Bergstrom, R., Lindgren, A., Nyren, O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340(11): 825-31.
3. Eckardt, V.F., Kanzler, G., Bernhard, G. Life expectancy and cancer risk in patients with Barrett's esophagus: A prospective controlled investigation. Am J Med 2001, 111(1): 33-7.
4. Lundell, L.R., Dent, J., Bennett, J.R. et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999, 45(2): 172-80.
5. Holtmann, G., Gschossmann, J., Buenger, L., Gerken, G., Talley, N.J. Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin? Gastroenterology 2002, 123(5): 1451-8.
6. Mönnikes, H., Bardhan, K.D., Stanghellini, V., Berghöfer, P., Bethke, T.D., Armstrong, D. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest™ in erosive GERD. Digestion 2004, 69: 238-44.
7. Van Rensburg, C., Bardhan, K.D., Tulassay, Z. et al. Pantoprazole 40 mg is comparable to esomeprazole 40 mg for first and sustained symptom relief in patients with erosive gastroesophageal reflux disease (GERD). Gastroenterology 2005, 128, 4(Suppl. 2): A530.
8. Mönnikes, H., Raffenberger, B., Gatz, G., Hein, J. Novel measurement of rapid treatment success with ReQuest™: First and sustained symptom relief as outcome parameter in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion 2005, 71(3): 152-8.